Physician

Ajithkumar A Puthillath, MD

According to 2025 Medicare claims, Ajithkumar Puthillath, MD (NPI: 1225275233) practices medical oncology in the Stockton-Lodi, CA market, with the plurality of this provider's patient population coming from San Joaquin, CA. This provider's primary affiliated billing organization is STOCKTON HEMATOLOGY ONCOLOGY MEDICAL GROUP, INC (NPI: 1922175074; TIN: 20-3850829) and primary practice location at 95204-5500.

Puthillath's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 735 traditional Medicare patients, billed 240,870 HCPCS/CPT codes, and received $4,806,540 in Medicare payments. The top billing code was 78815 (Nuclear medicine study from skull base to mid-thigh with ct scan). Part D data shows 2,160 prescription claims across 395 beneficiaries totaling $6,328,113 in drug costs, led by Revlimid (Lenalidomide). DME data shows 52 claims. Open Payments data shows 79 records totaling $3,554. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,339,442 to $4,806,540. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,577,801 to $6,328,113. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,624 to $2,238.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	741	140,371	$2,339,442
2016	614	155,425	$2,464,891
2017	672	195,155	$3,835,381
2018	751	238,292	$4,247,007
2019	690	188,131	$3,863,668
2020	655	225,771	$4,459,746
2021	608	180,632	$3,350,801
2022	615	202,534	$3,750,336
2023	698	232,349	$4,842,908
2024	735	240,870	$4,806,540

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	264	1,648	$1,577,801
2016	284	1,772	$1,866,003
2017	287	1,538	$2,071,845
2018	301	1,601	$2,436,932
2019	292	1,809	$2,967,137
2020	343	2,362	$4,506,499
2021	317	2,113	$4,806,588
2022	339	2,105	$5,440,770
2023	363	2,073	$5,431,380
2024	395	2,160	$6,328,113

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	119	$62,532
2016	N/R	57	$23,102
2017	N/R	105	$29,620
2018	22	107	$15,850
2019	N/R	64	$6,139
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	29	$2,496
2024	N/R	52	$1,580

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78815	Nuclear medicine study from skull base to mid-thigh with ct scan	111	155	$1,359
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	108	149	$136
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	505	1,160	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	237	320	$65
96372	Injection of drug or substance under skin or into muscle	118	491	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	47	1,316	$775,457
Pomalyst	Pomalidomide	37	1,036	$664,810
Tagrisso	Osimertinib Mesylate	37	1,110	$578,953
Imbruvica	Ibrutinib	26	728	$423,978
Cabometyx	Cabozantinib S-Malate	17	510	$399,307

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	26	$1,128
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	26	$452

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	78	$2,489	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$1,065	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ajithkumar A. Puthillath, MD?

Tedicare shows public-source Medicare data for Ajithkumar A. Puthillath, MD (NPI 1225275233), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ajithkumar A. Puthillath, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ajithkumar A. Puthillath, MD?

Ajithkumar A. Puthillath, MD is linked to STOCKTON HEMATOLOGY ONCOLOGY MEDICAL GROUP, INC (billing NPI 1922175074) in the available physician profile data.

Does Ajithkumar A. Puthillath, MD have Open Payments data?

Ajithkumar A. Puthillath, MD has 79 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.